You are here:

edoxaban (Lixiana)

Advice

following a full submission

edoxaban (Lixiana®) is accepted for use within NHS Scotland.

Indication under review: Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

One phase III study showed non-inferiority of edoxaban versus a vitamin K antagonist for venous thromboembolism recurrence in patients who had received at least five days treatment with low molecular weight heparin or unfractionated heparin.  Edoxaban was also associated with a significant reduction in the risk of major and clinically relevant non-major bleeding (composite endpoint).

Drug Details

Drug Name: edoxaban (Lixiana)
SMC Drug ID: 1090/15
Manufacturer: Daiichi Sankyo UK Ltd
Indication: Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Accepted
Date Advice Published: 9 November 2015

Back